{"title":"Cellular senescence in renal ischemia-reperfusion injury.","authors":"Ying Chen, Li Yang","doi":"10.1097/CM9.0000000000003698","DOIUrl":"https://doi.org/10.1097/CM9.0000000000003698","url":null,"abstract":"<p><strong>Abstract: </strong>Acute kidney injury (AKI) affects more than 20% of hospitalized patients and is a significant contributor to morbidity and mortality, primarily due to ischemia/reperfusion injury (IRI), which is one of the leading causes of AKI. IRI not only exacerbates the immediate impact of AKI but also facilitates its progression to chronic kidney disease (CKD) and, in cases of preexisting CKD, to end-stage renal disease (ESRD). One of the critical pathological processes associated with IRI-AKI is cellular senescence, characterized by an irreversible arrest in the cell cycle, morphological and chromatin organization changes, altered transcriptional and metabolic profiles, and the development of a hypersecretory phenotype known as the senescence-associated secretory phenotype (SASP). The SASP amplifies senescence signals in surrounding normal cells through senescence-related pathways, contributing to tissue damage, fibrosis, and chronic inflammation. This review provides an overview of the defining features of senescent cells and explores the fundamental mechanisms underlying senescent cell generation following IRI. We elucidate the pivotal roles of cellular senescence in the transition from IRI-AKI to chronic kidney injury. Furthermore, we discuss emerging therapies targeting cellular senescence, including senolytics and senomorphics, which have shown promising results in both preclinical and clinical settings. These therapies position cellular senescence as a crucial target for the treatment of IRI in the kidneys. Additionally, advancements in single-cell sequencing technology and artificial intelligence-assisted drug screening are expected to accelerate the discovery of novel senescent biomarkers and synotherapeutics, paving the way for optimized and personalized therapeutic interventions.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Decoding the immune microenvironment of secondary chronic myelomonocytic leukemia due to DLBCL with CD19 CAR-T failure by single-cell RNA-seq.","authors":"Xudong Li, Hong Huang, Fang Wang, Mengjia Li, Binglei Zhang, Jianxiang Shi, Yuke Liu, Mengya Gao, Mingxia Sun, Haixia Cao, Danfeng Zhang, Na Shen, Weijie Cao, Zhilei Bian, Haizhou Xing, Wei Li, Linping Xu, Shiyu Zuo, Yongping Song","doi":"10.1097/CM9.0000000000003690","DOIUrl":"https://doi.org/10.1097/CM9.0000000000003690","url":null,"abstract":"<p><strong>Background: </strong>Several studies have demonstrated the occurrence of secondary tumors as a rare but significant complication of chimeric antigen receptor T (CAR-T) cell therapy, underscoring the need for a detailed investigation. Given the limited variety of secondary tumor types reported to date, a comprehensive characterization of the various secondary tumors arising after CAR-T therapy is essential to understand the associated risks and to define the role of the immune microenvironment in malignant transformation. This study aims to characterize the immune microenvironment of a newly identified secondary tumor post-CAR-T therapy, to clarify its pathogenesis and potential therapeutic targets.</p><p><strong>Methods: </strong>In this study, the bone marrow (BM) samples were collected by aspiration from the primary and secondary tumors before and after CD19 CAR-T treatment. The CD45+ BM cells were enriched with human CD45 microbeads. The CD45+ cells were then sent for 10× genomics single-cell RNA sequencing (scRNA-seq) to identify cell populations. The Cell Ranger pipeline and CellChat were used for detailed analysis.</p><p><strong>Results: </strong>In this study, a rare type of secondary chronic myelomonocytic leukemia (CMML) were reported in a patient with diffuse large B-cell lymphoma (DLBCL) who had previously received CD19 CAR-T therapy. The scRNA-seq analysis revealed increased inflammatory cytokines, chemokines, and an immunosuppressive state of monocytes/macrophages, which may impair cytotoxic activity in both T and natural killer (NK) cells in secondary CMML before treatment. In contrast, their cytotoxicity was restored in secondary CMML after treatment.</p><p><strong>Conclusions: </strong>This finding delineates a previously unrecognized type of secondary tumor, CMML, after CAR-T therapy and provide a framework for defining the immune microenvironment of secondary tumor occurrence after CAR-T therapy. In addition, the results provide a rationale for targeting macrophages to improve treatment strategies for CMML treatment.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chinese Medical JournalPub Date : 2025-07-05Epub Date: 2025-04-11DOI: 10.1097/CM9.0000000000003493
Na Li, Jingwei Mao, Haiying Tang, Xiaoyan Tan, Jian Bi, Hao Wu, Xiuli Chen, Yingde Wang
{"title":"FLT3 ligand regulates expansion of regulatory T-cells induced by regulatory dendritic cells isolated from gut-associated lymphoid tissues through the Notch pathway.","authors":"Na Li, Jingwei Mao, Haiying Tang, Xiaoyan Tan, Jian Bi, Hao Wu, Xiuli Chen, Yingde Wang","doi":"10.1097/CM9.0000000000003493","DOIUrl":"10.1097/CM9.0000000000003493","url":null,"abstract":"<p><strong>Background: </strong>Regulatory dendritic cell (DCreg) subset exhibits a unique capacity for inducing immune tolerance among the variety subsets of dendritic cells (DCs) within gut-associated lymphoid tissues (GALTs). Fms-like tyrosine kinase 3 ligand (FLT3L) is involved in the differentiation of DCregs and the subsequent expansion of regulatory T-cells (Tregs) mediated by DCregs, though the precise mechanism remains poorly understood. This study aimed to explore the expansion mechanism of Treg induced by DCreg and the role of FLT3L in this process.</p><p><strong>Methods: </strong>DCregs were distinguished from other DC subsets isolated from GALTs of BALB/c mice through a mixed lymphocyte reaction assay. The functions and mechanisms by which FLT3L promoted Treg expansion via DCregs were investigated in vitro through co-culture experiments involving DCregs and either CD4 + CD25 - T-cells or CD4 + CD25 + T-cells. Additionally, an in vivo experiment was conducted using a dextran sulfate sodium (DSS)-induced colitis model in mice.</p><p><strong>Results: </strong>CD103 + CD11b + DC exhibited DCreg-like functionality and was identified as DCreg for subsequent investigation. Analysis of Foxp3 + Treg percentages within a co-culture system of CD4 + CD25 - T-cells and DCregs, with or without FLT3L, demonstrated the involvement of the FLT3/FLT3L axis in driving the differentiation of precursor T-cells into Foxp3 + Tregs induced by DCregs. Cell migration and co-culture assays revealed that the FLT3/FLT3L axis enhanced DCreg migration toward Tregs via the Rho pathway. Additionally, it was observed that DCregs could promote Treg proliferation through the Notch pathway, as inhibition of Notch signaling by DAPT (N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester) suppressed Treg expansion within the co-culture system of DCregs and CD4 + T-cells or CD4 + CD25 + T-cells. Furthermore, the FLT3/FLT3L axis influenced JAG1 expression in DCregs, indirectly modulating Treg expansion. In vivo experiments further established that FLT3L promoted DCreg expansion and restored Treg balance in DSS-induced colitis models, thereby ameliorating colitis symptoms in mice.</p><p><strong>Conclusion: </strong>The FLT3/FLT3L axis is integral to the maintenance of DCreg function in Treg expansion.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"1595-1606"},"PeriodicalIF":7.5,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chinese Medical JournalPub Date : 2025-07-05Epub Date: 2025-05-13DOI: 10.1097/CM9.0000000000003595
Li Zhang, Jinhua Xu, Chaoying Gu, Min Zheng, Meng Pan, Linfeng Li, Michael Lane, Andrew Platt, Shereen Hammad, Qichen Fan, Xinghua Gao
{"title":"Efficacy and safety of upadacitinib through 140 weeks in Chinese adult and adolescent patients with moderate-to-severe atopic dermatitis: Post hoc analysis of the phase 3 Measure Up 1 and AD Up clinical trials.","authors":"Li Zhang, Jinhua Xu, Chaoying Gu, Min Zheng, Meng Pan, Linfeng Li, Michael Lane, Andrew Platt, Shereen Hammad, Qichen Fan, Xinghua Gao","doi":"10.1097/CM9.0000000000003595","DOIUrl":"10.1097/CM9.0000000000003595","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"1633-1634"},"PeriodicalIF":7.5,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chinese Medical JournalPub Date : 2025-07-05Epub Date: 2024-09-23DOI: 10.1097/CM9.0000000000003299
Baiqiang Dong, Shuohan Zheng, Kelly Chen, Xuan Zhu, Sijuan Huang, Xiaobo Jiang, Wenchao Diao, Hua Li, Lecheng Jia, Feng Chi, Xiaoyan Huang, Qiwen Li, Ming Chen
{"title":"Key technologies and challenges in online adaptive radiotherapy for lung cancer.","authors":"Baiqiang Dong, Shuohan Zheng, Kelly Chen, Xuan Zhu, Sijuan Huang, Xiaobo Jiang, Wenchao Diao, Hua Li, Lecheng Jia, Feng Chi, Xiaoyan Huang, Qiwen Li, Ming Chen","doi":"10.1097/CM9.0000000000003299","DOIUrl":"10.1097/CM9.0000000000003299","url":null,"abstract":"<p><strong>Abstract: </strong>Definitive treatment of lung cancer with radiotherapy is challenging, as respiratory motion and anatomical changes can increase the risk of severe off-target effects during radiotherapy. Online adaptive radiotherapy (ART) is an evolving approach that enables timely modification of a treatment plan during the interfraction of radiotherapy, in response to physiologic or anatomic variations, aiming to improve the dose distribution for precise targeting and delivery in lung cancer patients. The effectiveness of online ART depends on the seamless integration of multiple components: sufficient quality of linear accelerator-integrated imaging guidance, deformable image registration, automatic recontouring, and efficient quality assurance and workflow. This review summarizes the present status of online ART for lung cancer, including key technologies, as well as the challenges and areas of active research in this field.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"1559-1567"},"PeriodicalIF":7.5,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233929/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chinese Medical JournalPub Date : 2025-07-05Epub Date: 2024-07-11DOI: 10.1097/CM9.0000000000003193
Kuanyu Xia, Lang Min, Wenqing Xie, Guang Yang, Dong Keon Yon, Seung Won Lee, Ai Koyanagi, Louis Jacob, Lee Smith, Jae Il Shin, Masoud Rahmati, Wenfeng Xiao, Yusheng Li
{"title":"Is unicompartmental knee arthroplasty a better choice than total knee arthroplasty for unicompartmental osteoarthritis? A systematic review and meta-analysis of randomized controlled trials.","authors":"Kuanyu Xia, Lang Min, Wenqing Xie, Guang Yang, Dong Keon Yon, Seung Won Lee, Ai Koyanagi, Louis Jacob, Lee Smith, Jae Il Shin, Masoud Rahmati, Wenfeng Xiao, Yusheng Li","doi":"10.1097/CM9.0000000000003193","DOIUrl":"10.1097/CM9.0000000000003193","url":null,"abstract":"<p><strong>Background: </strong>The choice of unicompartmental knee arthroplasty (UKA) vs . total knee arthroplasty (TKA) in the surgical treatment of knee osteoarthritis (KOA) remains controversial. This study aimed to perform a systematic review and meta-analysis of randomized controlled trials (RCTs) to compare the clinical results of UKA and TKA for treating unicompartmental KOA.</p><p><strong>Methods: </strong>PubMed, Embase, and the Cochrane Library were systematically searched for articles published up to January 2, 2023. The literature was rigorously screened to include only RCTs comparing UKA and TKA for unicompartmental KOA. A systematic review and meta-analysis were performed to calculate the mean difference (MD), relative risk (RR), and 95% confidence interval (CI) according to the Cochrane standards.</p><p><strong>Results: </strong>Thirteen publications involving 683 UKAs and 683 TKAs were analyzed. Except for one study with a follow-up period of 15 years, all outcome measures reported were within 5 years of follow-up. Meta-analysis showed better knee recovery (MD: 1.23; 95% CI: 1.01-1.45; P <0.001), greater knee function (MD: 1.78; 95% CI: 0.34-3.22; P = 0.020), less pain (MD: 0.75; 95% CI: 0.43-1.06; P <0.001), and better health status (MD: 3.75; 95% CI: 0.81-6.69; P = 0.010) after UKA than TKA. However, considering the minimal clinically important difference values for these variables, the findings were not clinically relevant. Moreover, UKA patients had fewer complications (RR: 0.59; 95% CI: 0.45-0.78; P <0.001) and shorter hospital stays (MD: -0.89; 95% CI: -1.57 to -0.22; P = 0.009) than did TKA patients. There were no statistically significant differences in terms of postoperative range of movement, revision, failure, operation time, and patient satisfaction.</p><p><strong>Conclusions: </strong>In terms of clinical efficacy, there was no obvious advantage of UKA over TKA in the surgical treatment of knee OA when considering the minimal clinically important difference. The main advantage of UKA over TKA is that it leads to fewer complications and a shorter length of hospital stay. It is ideal to perform prospective studies with longer follow-up periods to fully evaluate the long-term efficacy and safety of the two procedures in the future.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"1568-1577"},"PeriodicalIF":7.5,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233926/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141598773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prognostic impact of systemic inflammatory response index in patients with myocardial infarction with non-obstructive coronary arteries.","authors":"Yanwen Fang, Haihua Zhang, Sizhuang Huang, Mengyue Yu","doi":"10.1097/CM9.0000000000003523","DOIUrl":"10.1097/CM9.0000000000003523","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"1621-1623"},"PeriodicalIF":7.5,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144092903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chinese Medical JournalPub Date : 2025-07-05Epub Date: 2025-06-11DOI: 10.1097/CM9.0000000000003717
Lan Zhu, Zichen Zhao, Attilio Di Spiezio Sardo, Maribel Acién, Joel Naftalin, Thierry Van den Bosch, Charleen Sze-Yan Cheung, Dabao Xu, Xiaowu Huang, Grigoris Grimbizis
{"title":"Euro-Chinese consensus on accessory cavitated uterine malformation.","authors":"Lan Zhu, Zichen Zhao, Attilio Di Spiezio Sardo, Maribel Acién, Joel Naftalin, Thierry Van den Bosch, Charleen Sze-Yan Cheung, Dabao Xu, Xiaowu Huang, Grigoris Grimbizis","doi":"10.1097/CM9.0000000000003717","DOIUrl":"10.1097/CM9.0000000000003717","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"1526-1528"},"PeriodicalIF":7.5,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}